Cathepsins are involved in a variety of physiological processes including antigen processing and presentation and extracellular matrix degradation. In the present study, we evaluated whether expression levels of
cathepsins S and B and their inhibitors
cystatins B and C are affected by
multiple sclerosis (MS) disease state (relapse and remission) and
therapies (
interferon-β [IFN-β] and the
glucocorticoid [GC]
methylprednisolone), and whether they are associated with the IFN-β response phenotype. Real-time PCR was employed to compare
RNA expression levels in peripheral blood leucocytes (PBLs) and ELISA to determine
serum protein levels of MS patients and matched healthy individuals.
Cathepsin S RNA was higher in MS patients in the relapse state compared to controls (by 74%, P = 3 × 10(-5),
n = 30 versus n = 18) with a similar increase observed in serum (66%, P = 0.002, n = 18 versus n = 20). GC treatment reduced
cathepsin S levels in PBL
RNA (by 44%, P = 6 × 10(-6), n = 27) and
serum proteins (by 27%, P = 1 × 10(-5), n = 26), reduced the
serum protein levels of pro-
cathepsin B (by 8%, P = 0.0007, n = 23), and in parallel increased the serum levels of their inhibitor
cystatin C (by 82%, P = 8 × 10(-6), n = 26). IFN-β
therapy significantly elevated the
RNA levels (n = 16) of
cathepsin B (by 16%, P = 0.03),
cystatin B (44%, P = 0.004) and
cystatin C (48%, P = 0.011). In the serum, only
cathepsin S levels were reduced by IFN-β (16%, P = 0.006, n = 25). Interestingly, pre-treatment serum
cathepsin S/
cystatin C ratio was higher in 'good responders' to IFN-β
therapy compared to patients without a good response (by 94%, P = 0.003). These results suggest that
cathepsin S and
cystatin C may contribute to disease activity in MS, specifically in a subgroup of patients that are responsive to IFN-β
therapy, and that these
proteins should be further evaluated as
biomarkers in MS.